Navigation Links
Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
Date:8/4/2010

QUÉBEC CITY, Aug. 4 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, will announce its second quarter 2010 financial and operating results before market open on Thursday, August 12, 2010. The Company will host a conference call and webcast to discuss these results later that same day at 1:30 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: in Canada, 514-807-9895 or 647-427-7451, outside Canada, 888-231-8191. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
2. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
3. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
4. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
5. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
6. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
7. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
8. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
9. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
10. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
11. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 2017 , ... Biologist Dawn Maslar MS has found a biomarker that she ... Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding True Love, ... logical next step, in my estimation, was to scientifically track the evidence of commitment ...
(Date:6/20/2017)... ... June 20, 2017 , ... National executive search firm, ... extensive assay development and biomarker expertise, as VP of Scientific Affairs at Cambridge ... in bio-analytical assay development and sample testing services. The organization acts as a ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... overseeing all service activities supporting EDETEK’s products including training, implementation, support, and client ... to his new role. He has previously held leadership roles for service providers ...
(Date:6/19/2017)... Iowa (PRWEB) , ... June 19, 2017 , ... A ... interplay among its cells and tissues by delivering pollen and nectar containing nutrients necessary ... the means to stay healthy. , Many recent indicators point to a decline in ...
Breaking Biology Technology:
(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):